# Biomarker Correlates of Hypoxia in Metastatic Melanoma

> **NCT02061007** · PHASE2 · WITHDRAWN · sponsor: **H. Lee Moffitt Cancer Center and Research Institute**

## Conditions studied

- Melanoma
- Skin Cancer

## Interventions

- **DRUG:** Pimonidazole hydrochloride (Hypoxyprobe™-1)
- **DRUG:** Optional 18F-FMISO PET scan (18F-fluoromisonidazole)
- **PROCEDURE:** Surgical Resection of Melanoma Metastases

## Key facts

- **NCT ID:** NCT02061007
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-10
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** no accrual
- **Last updated:** 2016-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02061007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02061007, "Biomarker Correlates of Hypoxia in Metastatic Melanoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02061007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*